Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
OBJECTIVE
Skin sclerosis that progresses in the earlier disease phase in systemic sclerosis (SSc) spontaneously regresses thereafter. We investigated the relationship between changes of the serum cytokine profile and changes in skin fibrosis in patients with SSc.


METHODS
Serum cytokine levels were examined by ELISA using 180 sera samples from 26 patients with early diffuse cutaneous SSc (dcSSc) with mean disease duration of 2.1 years. The mean followup period was 4.9 years (range 2-8). Cytokine mRNA expression in the affected skin was quantified by real-time reverse transcription-polymerase chain reaction.


RESULTS
Modified Rodnan total skin thickness score decreased after 2, 4, and 6 years compared to that at first visit. Serum levels of the Th2 cytokines interleukin 6 (IL-6) and IL-10 and monocyte chemotactic protein-1 (MCP-1) were higher at first evaluation compared to healthy controls, while IL-4 levels were normal. Levels of all Th2 cytokines generally decreased as skin sclerosis regressed. Conversely, levels of serum IL-12, a Th1-inducing cytokine, were lower at first visit relative to controls, but increased by roughly 15-fold after 6 years to significantly higher levels than controls. Surviving dcSSc patients exhibited elevated IL-12 levels compared to deceased patients. Serum levels of transforming growth factor-ss1 (TGF-ss1), a fibrogenic cytokine, increased throughout followup, with slightly decreased levels at later timepoints. IL-12 mRNA expression was upregulated in affected skin from patients with late-stage dcSSc, while TGF-ss1 and MCP-1 expression was downregulated.


CONCLUSIONS
These results suggest that a shift from Th2 to Th1 response correlates with improvement in skin fibrosis in SSc, and that IL-12 level is a serologically useful marker for disease activity and prognosis.
Matsushita
Takashi
T
Department of Dermatology, Kanazawa University Graduate School of Medical Science, Japan.
Hasegawa
Minoru
M
Hamaguchi
Yasuhito
Y
Takehara
Kazuhiko
K
Sato
Shinichi
S
D000328:Adult; D018932:Chemokine CCL2 / Q000097:blood / Q000235:genetics; D005260:Female; D005355:Fibrosis / Q000473:pathology; D015870:Gene Expression; D006801:Humans; D016753:Interleukin-10 / Q000097:blood / Q000235:genetics; D018664:Interleukin-12 / Q000097:blood* / Q000235:genetics; D015850:Interleukin-6 / Q000097:blood / Q000235:genetics; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000378:metabolism; D012075:Remission, Spontaneous; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012595:Scleroderma, Systemic / Q000097:blood* / Q000473:pathology; D012867:Skin / Q000473:pathology*; D016212:Transforming Growth Factor beta / Q000097:blood / Q000235:genetics; D053773:Transforming Growth Factor beta1
C111835:CCL2 protein, human; D018932:Chemokine CCL2; D015850:Interleukin-6; D012333:RNA, Messenger; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D016753:Interleukin-10; D018664:Interleukin-12